News
Public · Published
Alnylam Pharmaceuticals Price Target Cut to $354.00/Share From $482.00 by TD Cowen
TD Cowen cut its price target on Alnylam Pharmaceuticals to $354.00 per share from $482.00, while keeping a Buy rating on the stock, according to the supplied ratings note.
Published:
Updated:
What happened
TD Cowen cut its price target on Alnylam Pharmaceuticals to $354.00 per share from $482.00, while keeping a Buy rating on the stock, according to the supplied ratings note.
Confirmed
Global impact / market context
A lower price target means the analyst expects less upside than before, even while still recommending the stock. This can prompt investors to reassess how much they are willing to pay per share, which may weigh on the share price.
Analyst inference
Price target changes are common analyst updates that reflect revised expectations for a company's future performance. Because the Buy rating was kept, the note signals continued positive views, but with a reduced expected payoff for investors holding or considering the stock.
Analyst inference
What to watch
- TD Cowen maintained its Buy rating on Alnylam Pharmaceuticals while lowering its price target to $354.00 per share from $482.00, according to the supplied ratings note. Confirmed
- Investors could compare this new target with the current share price to judge how much expected gain remains, though the article does not provide a current share price. Proposed
- Further analyst updates may show whether others share TD Cowen's reduced expectations, since the article reports only this single ratings action and no wider analyst consensus. Analyst inference
Evidence
- Original source link unavailable